Researchers from the Singapore-MIT Alliance for Research & Technology’s (SMART) Antimicrobial Resistance (AMR) interdisciplinary research group, alongside collaborators from Massachusetts Institute of Technology (MIT), Nanyang Technological University (NTU Singapore), and institutions in the United States, Poland and France, have discovered aminovaleramididine synthetase (AvaS), the first identified pyridoxal phosphate (PLP)-dependent enzyme responsible for producing a chemical modification linked to how bacteria respond to metabolic stress.

This fundamental discovery sheds new light on how bacteria use RNA modification to control protein production, opening new avenues to study bacterial adaptation and identify future targets for antimicrobial therapeutics.

Antimicrobial resistance is one of the most pressing global health and development challenges of our time. Bacteria and other pathogens are rapidly developing resistance to existing treatments, making infections harder to treat. Without new approaches, minor inconveniences today, such as routine surgeries or even a paper cut, could become life-threatening tomorrow.